- TKMR has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $8.5 million.
- TKMR has traded 206,063 shares today.
- TKMR is trading at 2.24 times the normal volume for the stock at this time of day.
- TKMR is trading at a new high 7.35% above yesterday's close.
'Strong on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as M&A events, material stock news, analyst upgrades, insider buying, buying from 'superinvestors,' or that hedge funds and momentum traders are piling into a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize. In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success. EXCLUSIVE OFFER: Get the inside scoop on opportunities in TKMR with the Ticky from Trade-Ideas. See the FREE profile for TKMR NOW at Trade-Ideas More details on TKMR: Tekmira Pharmaceuticals Corporation, a biopharmaceutical company, focuses on the research and development of RNA interference therapeutics; and provides lipid nanoparticle delivery technology to pharmaceutical partners in Canada. Currently there are 4 analysts that rate Tekmira Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold. The average volume for Tekmira Pharmaceuticals has been 3.4 million shares per day over the past 30 days. Tekmira has a market cap of $286.3 million and is part of the health care sector and drugs industry. Shares are up 61.9% year-to-date as of the close of trading on Monday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Tekmira Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and weak operating cash flow. Highlights from the ratings report include:
- The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 41.4% when compared to the same quarter one year ago, falling from -$6.08 million to -$8.60 million.
- Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Biotechnology industry and the overall market, TEKMIRA PHARMACEUTICALS CORP's return on equity significantly trails that of both the industry average and the S&P 500.
- Net operating cash flow has significantly decreased to -$6.72 million or 78.91% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
- TEKMIRA PHARMACEUTICALS CORP has improved earnings per share by 7.1% in the most recent quarter compared to the same quarter a year ago. This company has not demonstrated a clear trend in earnings over the past 2 years, making it difficult to accurately predict earnings for the coming year. During the past fiscal year, TEKMIRA PHARMACEUTICALS CORP swung to a loss, reporting -$0.96 versus $1.87 in the prior year.
- Investors have driven up the company's shares by 59.04% over the past year, a rise that has exceeded that of the S&P 500 Index. Regarding the future course of this stock, we feel that the risks involved in investing in TKMR do not compensate for any future upside potential, despite the fact that it has seen nice gains over the past 12 months.
- You can view the full Tekmira Pharmaceuticals Ratings Report.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.